Physician profile
Todd Larue
NPI 1912920950
$3,983.64
in general payments reported to CMS, 2019-2025
26 companies · $576 in 2025
The $576 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $545 · 2021: $910 · 2022: $579 · 2023: $301 · 2024: $339 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $849.34 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $627.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $283.28 | 2019-2022 | |
| Pfizer INC. | $280.59 | 2019-2025 | |
| Glaxosmithkline, LLC. | $279.82 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $198.69 | 2019-2025 | Mounjaro, Jardiance, Synjardy |
| Exact Sciences Corporation | $165.09 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $150.08 | 2019-2025 | Airsupra |
| Esperion Therapeutics, INC. | $130.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $123.78 | 2021-2022 | |
| Dexcom, INC. | $111.47 | 2021-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $96.12 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $86.25 | 2019-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.66 | 2021-2025 | Jardiance |
| Dynavax Technologies Corporation | $74.18 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $68.74 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $66.85 | 2019-2021 | |
| Abbott Laboratories | $65.63 | 2020-2022 | |
| Sanofi Pasteur INC. | $60.26 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $36.50 | 2019 | |
| Allergan, INC. | $35.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $29.73 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.54 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.16 | 2021 | |
| Almatica Pharma LLC | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Larue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.